Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2)

Takeuchi, Mai; Katayama, Yoshio; Okamura, Atsuo; Yamamoto, Katsuya; Shimoyama, Manabu; Matsui, Toshimitsu

doi:10.1016/j.cancergencyto.2007.08.010

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the literature, a number of other CML cases with t(9;22;21)(q34;q11;q22) (10)(11)(12)(13)(14)(15), one case with t(9;22;21) (q34;q11;q21) (16) and one with t(9;22;21)(q34;q11;q11.2) (17) have been reported, respectively. To the best of our knowledge, only one case of Ph chromosome-positive CML with a unique translocation of three chromosomes t(9;22;21)(q34;q11;p12) was detected, and this translocation has yet to be observed at 21p12 in CML (18).…”

Section: Discussionmentioning

confidence: 99%

A chronic myeloid leukemia case with a unique variant Philadelphia translocation: t(9;22;21)(q34;q11;p12)

et al. 2012

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A chronic myeloid leukemia case with a unique variant Philadelphia translocation: t(9;22;21)(q34;q11;p12)

et al. 2012

View full text Add to dashboard Cite

“…Secondly, it is well known that chronic myeloid leukaemia (CML) is a disease guided via a molecular defect on the BCR‐ABL translocation, resulting in: activation and dysregulation of a large number of signalling pathways, including cell division changes and also genetic‐abnormalities incorporation . In fact, BCR‐ABL tyrosine kinase inhibitor was introduced in CML therapy as being one of the major advances in leukaemia treatments.…”

Section: Introductionmentioning

confidence: 99%

Proteomics‐based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunities

Villar

Cho

et al. 2014

J Cellular Molecular Medi

View full text Add to dashboard Cite

There are important breakthroughs in the treatment of paediatric acute lymphoblastic leukaemia (ALL) since 1950, by which the prognosis of the child majority suffered from ALL has been improved. However, there are urgent needs to have disease-specific biomarkers to monitor the therapeutic efficacy and predict the patient prognosis. The present study overviewed proteomics-based research on paediatric ALL to discuss important advances to combat cancer cells and search novel and real protein biomarkers of resistance or sensitivity to drugs which target the signalling networks. We highlighted the importance and significance of a proper phospho-quantitative design and strategy for paediatric ALL between relapse and remission, when human body fluids from cerebrospinal, peripheral blood, or bone-marrow were applied. The present article also assessed the schedule for the analysis of body fluids from patients at different states, importance of proteomics-based tools to discover ALL-specific and sensitive biomarkers, to stimulate paediatric ALL research via proteomics to ‘build’ the reference map of the signalling networks from leukemic cells at relapse, and to monitor significant clinical therapies for ALL-relapse.

show abstract

Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2)

Cited by 2 publications

References 13 publications

A chronic myeloid leukemia case with a unique variant Philadelphia translocation: t(9;22;21)(q34;q11;p12)

A chronic myeloid leukemia case with a unique variant Philadelphia translocation: t(9;22;21)(q34;q11;p12)

Proteomics‐based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunities

Contact Info

Product

Resources

About